Leukemia, Prolymphocytic, T-Cell
"Leukemia, Prolymphocytic, T-Cell" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A lymphoid leukemia characterized by a profound LYMPHOCYTOSIS with or without LYMPHADENOPATHY, hepatosplenomegaly, frequently rapid progression, and short survival. It was formerly called T-cell chronic lymphocytic leukemia.
MeSH Number(s)
C04.557.337.428.565.750
C04.557.337.428.580.125
C15.604.515.560.550.750
C15.604.515.560.575.125
C20.683.515.528.565.750
C20.683.515.528.582.125
Concept/Terms
Leukemia, Prolymphocytic, T-Cell- Leukemia, Prolymphocytic, T-Cell
- T-Cell Prolymphocytic Leukemia
- Leukemia, T-Cell Prolymphocytic
- Leukemias, T-Cell Prolymphocytic
- Prolymphocytic Leukemia, T-Cell
- Prolymphocytic Leukemias, T-Cell
- T Cell Prolymphocytic Leukemia
- T-Cell Prolymphocytic Leukemias
Leukemia, T Cell, Chronic- Leukemia, T Cell, Chronic
- Leukemia, Lymphocytic, Chronic, T-Cell
- T-Lymphocytic Leukemia, Chronic
- Lymphocytic Leukemia, T Cell, Chronic
- Lymphocytic Leukemia, T-Cell, Chronic
- T-Cell Leukemia, Chronic
- Leukemia, Lymphocytic, Chronic, T Cell
- Leukemia, T-Cell, Chronic
Below are MeSH descriptors whose meaning is more general than "Leukemia, Prolymphocytic, T-Cell".
- Diseases [C]
- Neoplasms [C04]
- Neoplasms by Histologic Type [C04.557]
- Leukemia [C04.557.337]
- Leukemia, Lymphoid [C04.557.337.428]
- Leukemia, Prolymphocytic [C04.557.337.428.565]
- Leukemia, Prolymphocytic, T-Cell [C04.557.337.428.565.750]
- Leukemia, T-Cell [C04.557.337.428.580]
- Leukemia, Prolymphocytic, T-Cell [C04.557.337.428.580.125]
- Hemic and Lymphatic Diseases [C15]
- Lymphatic Diseases [C15.604]
- Lymphoproliferative Disorders [C15.604.515]
- Leukemia, Lymphoid [C15.604.515.560]
- Leukemia, Prolymphocytic [C15.604.515.560.550]
- Leukemia, Prolymphocytic, T-Cell [C15.604.515.560.550.750]
- Leukemia, T-Cell [C15.604.515.560.575]
- Leukemia, Prolymphocytic, T-Cell [C15.604.515.560.575.125]
- Immune System Diseases [C20]
- Immunoproliferative Disorders [C20.683]
- Lymphoproliferative Disorders [C20.683.515]
- Leukemia, Lymphoid [C20.683.515.528]
- Leukemia, Prolymphocytic [C20.683.515.528.565]
- Leukemia, Prolymphocytic, T-Cell [C20.683.515.528.565.750]
- Leukemia, T-Cell [C20.683.515.528.582]
- Leukemia, Prolymphocytic, T-Cell [C20.683.515.528.582.125]
Below are MeSH descriptors whose meaning is more specific than "Leukemia, Prolymphocytic, T-Cell".
This graph shows the total number of publications written about "Leukemia, Prolymphocytic, T-Cell" by people in Harvard Catalyst Profiles by year, and whether "Leukemia, Prolymphocytic, T-Cell" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2009 | 1 | 0 | 1 |
2012 | 0 | 1 | 1 |
2013 | 1 | 0 | 1 |
2014 | 1 | 0 | 1 |
2017 | 2 | 0 | 2 |
2019 | 1 | 0 | 1 |
2020 | 1 | 0 | 1 |
2021 | 2 | 0 | 2 |
2023 | 1 | 0 | 1 |
Below are the most recent publications written about "Leukemia, Prolymphocytic, T-Cell" by people in Profiles.
-
Recurrence of T-Cell Prolymphocytic Leukemia With a Rare Presentation as Diffuse Generalized Skin Lesion. J Investig Med High Impact Case Rep. 2023 Jan-Dec; 11:23247096231176223.
-
An unusual case of T-cell prolymphocytic leukemia mimicking a cutaneous vasculitis. J Cutan Pathol. 2021 Oct; 48(10):1311-1316.
-
BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia. Blood. 2021 06 24; 137(25):3495-3506.
-
Combining epigenetic therapy with venetoclax overcomes alemtuzumab resistance in T-cell prolymphocytic leukemia. A case report of a 26-year-old man with a prior history of T-cell acute lymphoblastic leukemia and GI-T lymphoma. Acta Oncol. 2020 Dec; 59(12):1547-1551.
-
T-Cell Dynamics in Chronic Lymphocytic Leukemia under Different Treatment Modalities. Clin Cancer Res. 2020 09 15; 26(18):4958-4969.
-
Dual dependence on BCL2 and MCL1 in T-cell prolymphocytic leukemia. Blood Adv. 2020 02 11; 4(3):525-529.
-
Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia. Blood. 2019 10 03; 134(14):1132-1143.
-
First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia. Blood. 2017 12 07; 130(23):2499-2503.
-
Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling. Leukemia. 2018 03; 32(3):774-787.
-
Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL). Ann Oncol. 2017 Jul 01; 28(7):1554-1559.